Interestingly, analysis of IL2–STAT5 signaling levels of NSCLC patients from TCGA showed high variability in pathway activity levels, suggesting that a sub-population of patients may benefit from treatment with BCL2 inhibitors such as ABT-263 and ABT-737 (Supplementary Fig. 5c). The gene discussed is IL2; the disease is non-small cell lung carcinoma.